Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Tested Erelzi’s Suffix On Multiple Fronts

Executive Summary

Evaluations of potential nonproprietary name suffixes for the US biosimilar to Amgen’s Enbrel included checks on Internet search engines and databases of abbreviations and proprietary names, as well as safety, trademark and phonetic analyses.

Advertisement

Related Content

Drug Review Profiles: Behind The Scenes At US FDA
Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
Biosimilar Sponsors Took Delivery Device Shortcuts For Erelzi, Amjevita
How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts
Amjevita Clinical Development Timeline
Amjevita Reviewers
FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel